Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Novak

Showing results (311-320 of 332) with videos related to

Pageof 34
Sort By:
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Proteomics. Clinical Applications|December 8, 2010
Comprehensive human urine standards for comparability and standardization in clinical proteome analysisHarald Mischak, Walter Kolch, Michalis Aivaliotis, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 10, 2025
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/VasculitisDorey A Glenn, Ashley W Carver, Margaret E Helmuth, et al.
The Journal of Clinical Investigation|March 28, 2025
Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathySindhuri Prakash, Nicholas J Steers, Yifu Li, et al.
The Journal of Clinical Investigation|June 15, 2026
Erratum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathySindhuri Prakash, Nicholas J Steers, Yifu Li, et al.
Molecular & Cellular Proteomics : MCP|December 30, 2009
Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1Yoshinao Wada, Anne Dell, Stuart M Haslam, et al.
European Journal of Clinical Investigation|April 24, 2012
Implementation of proteomic biomarkers: making it workHarald Mischak, John P A Ioannidis, Angel Argiles, et al.
Nature Immunology|February 3, 2026
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332<sub>gp120</sub> glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Identification of a broad and potent V3 glycan site bNAb targeting an N332<sub>gp120</sub> glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Iscience|August 9, 2023
Soluble prefusion-closed HIV-envelope trimers with glycan-covered basesAdam S Olia, Cheng Cheng, Tongqing Zhou, et al.
Pageof 34

Showing results (311-320 of 332) with videos related to

Sort By:
Pageof 34
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Proteomics. Clinical Applications|December 8, 2010
Comprehensive human urine standards for comparability and standardization in clinical proteome analysisHarald Mischak, Walter Kolch, Michalis Aivaliotis, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 10, 2025
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/VasculitisDorey A Glenn, Ashley W Carver, Margaret E Helmuth, et al.
The Journal of Clinical Investigation|March 28, 2025
Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathySindhuri Prakash, Nicholas J Steers, Yifu Li, et al.
The Journal of Clinical Investigation|June 15, 2026
Erratum to Loss of GalNAc-T14 links O-glycosylation defects to alterations in B cell homing in IgA nephropathySindhuri Prakash, Nicholas J Steers, Yifu Li, et al.
Molecular & Cellular Proteomics : MCP|December 30, 2009
Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1Yoshinao Wada, Anne Dell, Stuart M Haslam, et al.
European Journal of Clinical Investigation|April 24, 2012
Implementation of proteomic biomarkers: making it workHarald Mischak, John P A Ioannidis, Angel Argiles, et al.
Nature Immunology|February 3, 2026
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332<sub>gp120</sub> glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Biorxiv : the Preprint Server for Biology|September 18, 2025
Identification of a broad and potent V3 glycan site bNAb targeting an N332<sub>gp120</sub> glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Iscience|August 9, 2023
Soluble prefusion-closed HIV-envelope trimers with glycan-covered basesAdam S Olia, Cheng Cheng, Tongqing Zhou, et al.
Pageof 34